July 2024 SEHK Growth Companies With High Insider Ownership

In This Article:

As global markets navigate through a period of relative calm and anticipation of upcoming earnings reports, Hong Kong's market has shown resilience despite broader economic concerns. This backdrop sets a compelling stage for examining growth companies in the SEHK with high insider ownership, which can signal strong confidence in a company’s future from those who know it best.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

20.2%

104.1%

Fenbi (SEHK:2469)

32.6%

43%

Adicon Holdings (SEHK:9860)

22.4%

28.3%

Tian Tu Capital (SEHK:1973)

34%

70.5%

DPC Dash (SEHK:1405)

38.2%

90.2%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.7%

79.3%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Ocumension Therapeutics (SEHK:1477)

23.1%

93.7%

Zhejiang Leapmotor Technology (SEHK:9863)

15%

76.5%

Beijing Airdoc Technology (SEHK:2251)

28.7%

83.9%

Click here to see the full list of 54 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Xiamen Yan Palace Bird's Nest Industry

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Xiamen Yan Palace Bird's Nest Industry Co., Ltd. is involved in the research, development, production, and marketing of edible bird’s nest products in China, with a market capitalization of HK$4.52 billion.

Operations: The company generates revenue through various channels, including CN¥16.75 million from online distributors, CN¥509.04 million from offline distributors, CN¥824.40 million from direct online customer sales, CN¥351.17 million from direct offline customer sales, and CN¥262.89 million from e-commerce platforms.

Insider Ownership: 26.7%

Revenue Growth Forecast: 12.6% p.a.

Xiamen Yan Palace Bird's Nest Industry, a growth company with significant insider ownership, demonstrates solid financial health with high-quality earnings primarily from non-cash sources. The company's revenue and earnings are expected to grow annually by 12.6% and 15.6%, respectively, outpacing the Hong Kong market averages of 7.8% for revenue and 11.3% for earnings growth. Recent corporate actions include a dividend affirmation of RMB 2.15 per ten shares and amendments to its Articles of Association, underscoring active management engagement and shareholder alignment.